Blood Biomarker of Alzheimer's Disease (AD)

Completed

Conditions studied: Alzheimer Disease

In brief

Currently, no cures or disease modifying therapies exist for Alzheimer's disease (AD). This is partially due to the inability to detect the disease before it has progressed to a stage where there are clinical manifestations. The identification and validation of high throughput biomarkers to measure disease progression (as well as identify pre-clinical disease onset) is critical to the development of disease-modifying or even preventative therapies. In this study, we are testing a blood biomarker for stratification of Alzheimer's disease patients and healthy volunteers. This study may lead to future blood tests that may help earlier diagnosis of Alzheimer's disease and detect the disease progression.

Key facts

Study ID: NCT03340571
Run by: Duke University
People needed: 21
Starts: 2018-03-12
Expected to finish: 2019-07-31
Last updated by the study team: 2019-10-23

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Alzheimer's Disease Patients:
50 years and older
AD patient who is seen at the Memory Disorders Clinic
AD diagnosis
Non smoking
No cancer treatment in the last 5 years
Informed consent from the patient or the patient's legally authorized representative (LAR)
Patient and/or LAR able to read and speak English
Healthy Control Participants:
50 years and older
Non smoking
No cancer treatment in the last 5 years
Age matched to AD subject
Able to read and speak English

You may not qualify if…

Alzheimer's Disease Patients:
Known additional neurological disease
Healthy Control Participants:
Neurological degenerative diseases (such as Parkinson's, Alzheimer's or Huntington's)

Where it is running

Duke University — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.